Brought to you by 
Bayer markets GW Pharmaceuticals' cannabis drug; terminated
05 May 2021
Executive Summary
In its first commercial collaboration, GW Pharmaceuticals PLC, a company developing drugs derived from cannabis, licensed Bayer exclusive UK marketing rights to its sublingual cannabis extract spray. The candidate, in regulatory review to treat neuropathic pain and symptoms of multiple sclerosis, will be sold by prescription in the UK under the brandname Sativex.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer markets GW Pharmaceuticals' cannabis drug; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice